# Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

> **NCT00701883** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 183 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** MBX-8025
- **DRUG:** MBX-8025
- **DRUG:** Atorvastatin
- **DRUG:** MBX-8025
- **DRUG:** MBX-8025

## Key facts

- **NCT ID:** NCT00701883
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2015-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00701883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00701883, "Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00701883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*